Related Experiment Video
Updated: Jul 16, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study
H M Reims1, S E Kjeldsen, W E Brady
1Department of Cardiology, Ullevaal University Hospital, Oslo, Norway. henrik.reims@ioks.uio.no
Insights
Moderate alcohol intake in hypertensive patients did not alter the stroke risk reduction from losartan versus atenolol. Alcohol consumption lowered myocardial infarction risk but increased stroke risk with higher intake.
Area of Science:
- Cardiology
- Hypertension Research
- Clinical Pharmacology
Background:
- The Losartan Intervention For End point reduction in hypertension (LIFE) study established losartan's superiority over atenolol in hypertensive patients with left ventricular hypertrophy.
- Understanding the impact of alcohol consumption on cardiovascular outcomes in high-risk hypertensive populations is crucial for personalized treatment strategies.
Purpose of the Study:
- To investigate the influence of varying alcohol intake levels on the composite cardiovascular endpoint risk in hypertensive patients.
- To compare the efficacy of losartan versus atenolol in relation to alcohol consumption patterns.
Main Methods:
- A secondary analysis of the LIFE study cohort, comparing hazard ratios for cardiovascular events based on self-reported weekly alcohol consumption (abstainers, 1-7 drinks/week, >8 drinks/week).
- Adjustments were made for demographic and lifestyle factors including gender, age, smoking, exercise, and race.
- Blood pressure control and treatment randomization were assessed across different alcohol intake categories.
Main Results:
- Lower composite endpoint rates were observed in both moderate (1-7 drinks/week) and high (>8 drinks/week) alcohol consumers compared to abstainers.
- Myocardial infarction risk was significantly reduced across both alcohol consumption groups.
- Stroke risk showed a trend towards increase with higher alcohol intake (>8 drinks/week), while losartan demonstrated significant composite risk reduction compared to atenolol primarily in abstainers.
Conclusions:
- Moderate alcohol consumption does not negate the stroke risk reduction benefits of losartan compared to atenolol in high-risk hypertensives.
- Alcohol intake is associated with reduced myocardial infarction risk, but higher consumption may increase stroke risk.
- No significant alcohol-treatment interactions were found, suggesting differential effects on specific cardiovascular events.
Abstract:
The Losartan Intervention For End point reduction in hypertension (LIFE) study showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke, and myocardial infarction in hypertensives with left ventricular hypertrophy. We compared hazard ratios (HR) in 4287 and 685 participants who reported intakes of 1-7 and >8 drinks/week at baseline, respectively, with those in 4216 abstainers, adjusting for gender, age, smoking, exercise, and race. Within categories, clinical baseline characteristics, numbers randomized to losartan and atenolol, and blood pressure (BP) lowering were similar on the drug regimens. Overall BP control (<140/90 mmHg) at end of follow-up was similar in the categories. Composite end point rate was lower with 1-7 (24/1000 years; HR 0.87, P<0.05) and >8 drinks/week (26/1000 years; HR 0.80, NS) than in abstainers (27/1000 years). Myocardial infarction risk was reduced in both drinking categories (HR 0.76, P<0.05 and HR 0.29, P<0.001, respectively), while stroke risk tended to increase with >8 drinks/week (HR 1.21, NS). Composite risk was significantly reduced with losartan compared to atenolol only in abstainers (HR 0.81 95% confidence interval, CI (0.68, 0.96), P<0.05), while benefits for stroke risk reduction were similar among participants consuming 1-7 drinks/week (HR 0.73, P<0.05) and abstainers (HR 0.72, P<0.01). Despite different treatment benefits, alcohol-treatment interactions were nonsignificant. In conclusion, moderate alcohol consumption does not change the marked stroke risk reduction with losartan compared to atenolol in high-risk hypertensives. Alcohol reduces the risk of myocardial infarction, while the risk of stroke tends to increase with high intake.
More Related Videos
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension IV: Drug Therapy and Lifestyle Modifications

